Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Marginal Zone Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-204)

被引：2

作者：

Phillips, Tycel ^{[1
]}

Avigdor, Abraham ^{[2
,3
]}

Gurion, Ronit ^{[4
,5
]}

Patti, Caterina ^{[6
]}

Corradini, Paolo ^{[7
]}

Tani, Monica ^{[8
]}

Mehta, Amitkumar ^{[9
]}

Lossos, Izidore S. ^{[10
]}

Zinzani, Pier Luigi Luigi ^{[11
]}

Thieblemont, Catherine ^{[12
]}

Jurczak, Wojciech ^{[13
]}

Zheng, Fred ^{[14
]}

Rappold, Erica ^{[14
]}

Zhao, Wanying ^{[14
]}

Johnson, Peter

机构：

[1] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI USA

[2] Inst Hematol, Sheba Med Ctr, Ramat Gan, Israel

[3] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel

[4] Rabin Med Ctr, Inst Hematol, Petch Tikva, Israel

[5] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel

[6] Azienda Villa Sofia Cervello, Div Oncohematol, Palermo, Italy

[7] Univ Milan, Fdn IRCCS Ist Nazl Tumori, Milan, Italy

[8] Osped Ravenna, Azienda Unita Sanitaria Locale Romagna, Ravenna, Italy

[9] Univ Alabama Birmingham, Div Hematol Oncol, Dept Med, Birmingham, AL USA

[10] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[11] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy

[12] Univ Paris, Hop St Louis, AP HP, Hematooncol DMU DHI, Paris, France

[13] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland

[14] Southampton Gen Hosp, Canc Res UK Ctr, Southampton, Hants, England

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-147778

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

下载

页数：7

共 50 条

[31] Primary Analysis of the Tegar Study: A Phase II Study Exploring the Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab or Rituximab in Patients with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), or Waldenstrom Macroglobulinemia (WM)
Panayiotidis, Panayiotis
Tumyan, Gayane
Thieblemont, Catherine
Ptushkin, Vadim V.
Niebla, Ana Marin
Garcia-Sanz, Ramon
Zaritskey, Andrey
Le Gouill, Steven
Buske, Christian
Van Hoef, Marlies
Perretti, Thomas
Tomiczek, Monique S.
Stathis, Anastasios
BLOOD, 2020, 136
[32] Phase 2 study of zanubrutinib (BGB-3111) in patients with relapsed/refractory marginal zone lymphoma (R/R MZL).
Opat, Stephen
Marcus, Robert
Portell, Craig Anthony
Reed, William
Co, Melannie
Huang, Jane
Trotman, Judith
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[33] A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial
Oh, Sung Yong
Kim, Won Seog
Kim, Jin Seok
Chae, Yee Soo
Lee, Gyeong-Won
Eom, Hyeon Seok
Ryoo, Hun Mo
Lee, Suee
Kim, Seok Jin
Yoon, Dok Hyun
Won, Jong Ho
Hong, Junshik
Park, Jinny
Lee, Sang-Min
Hong, Jung Yong
Park, Eunkyung
Kim, Hyo Jung
Yang, Deok-Hwan
Kim, Hyo-Jin
Suh, Cheolwon
LEUKEMIA & LYMPHOMA, 2016, 57 (06) : 1406 - 1412
[34] Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label study
Deng, Lijuan
Li, Zhiming
Zhang, Huilai
Huang, Haiwen
Hu, Jianda
Liu, Lihong
Liu, Ting
Jin, Jie
Zhu, Zunmin
Li, Wenyu
Huang, Zhenqian
Huang, Wenrong
Zhou, Keshu
Yang, Haiyan
Zhang, Mingzhi
Ding, Kaiyang
Zhou, Hui
Hu, Yu
Shuang, Yuerong
Cao, Junning
Gao, Sujun
Li, Dengju
Sun, Zimin
Zhang, Qingyuan
Yi, Shuhua
Ji, Chunyan
Zhang, Liansheng
Hou, Cheng
Du, Yue
Wang, Weige
Zhao, Renbin
Song, Yuqin
Zhu, Jun
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (11) : 1742 - 1750
[35] Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma
Armand, Philippe
Janssens, Ann
Gritti, Giuseppe
Radford, John
Timmerman, John
Pinto, Antonio
Vilchez, Santiago Mercadal
Johnson, Peter
Cunningham, David
Leonard, John P.
Rodig, Scott J.
Martin-Regueira, Patricia
Sumbul, Anne
Samakoglu, Selda
Tang, Hao
Ansell, Stephen M.
BLOOD, 2021, 137 (05) : 637 - 645
[36] Primary Analysis of the Phase 2 ELARA Trial: Tisagenlecleucel Efficacy and Safety in Adult Patients with Relapsed/Refractory Follicular Lymphoma (r/r FL)
Schuster, Stephen J.
Dickinson, Michael
Dreyling, Martin
Martinez-Lopez, Joaquin
Kolstad, Arne
Butler, Jason
Ghosh, Monalisa
Popplewell, Leslie
Chavez, Julio C.
Bachy, Emmanuel
Kato, Koji
Harigae, Hideo
Kersten, Marie Jose
Andreadis, Charalambos
Riedell, Peter
Zia, Aiesha
Morisse, Mony Chenda
Fowler, Nathan Hale
Thieblemont, Catherine
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S403 - S404
[37] Phase 2 study of the safety and efficacy of INCB050465 in patients with relapsed or refractory (RA) diffuse large b-cell lymphoma (DLBCL) (CITADEL-202).
Coleman, Morton
Forero-Torres, Andres
Ribrag, Vincent
Chau, Ian
DeMarini, Douglas James
Zinzani, Pier Luigi
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[38] Patients with Relapsed/Refractory Marginal Zone Lymphoma in the MAGNIFY Phase IIIb Interim Analysis of Induction R2 Followed By Maintenance
Coleman, Morton
Andorsky, David Jacob
Yacoub, Abdulraheem
Melear, Jason M.
Fanning, Suzanne R.
Kolibaba, Kathryn S.
Lansigan, Frederick
Reynolds, Christopher M.
Nowakowski, Grzegorz S.
Gharibo, Mecide
Ahn, Erin
Li, Ju
Rummel, Mathias J.
Sharman, Jeff P.
BLOOD, 2020, 136
[39] Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial
Opat, Stephen
Tedeschi, Alessandra
Linton, Kim
McKay, Pamela
Hu, Bei
Chan, Henry
Jin, Jie
Zinzani, Pier Luigi
Browett, Peter
Coleman, Morton
Sobieraj-Teague, Magdalena
Ke, Xiaoyan
Sun, Mingyuan
Marcus, Robert
Portell, Craig A.
Zhou, Keshu
Thieblemont, Catherine
Co, Melannie
Wang, Weige
Tankersley, Chris
Zhou, Wenxiao
Cappellini, Massimo
Huang, Jane
Trotman, Judith
BLOOD, 2020, 136
[40] Efficacy and Safety of Tisagenlecleucel in Adult Patients With Relapsed/Refractory Follicular Lymphoma: Interim Analysis of the Phase 2 ELARA Trial
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (01) : 12 - 13

← 1 2 3 4 5 →